All In Biotech

Drug Trial Radar · NCT04353466

Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs

An Open-label, Investigator Initiated Clinical Trial to Asses Impact of Elelyso on Bone Involvement in Patients With Gaucher Disease Currently Treated With Other ERTs

Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 1, 2017

Primary completion

Jul 31, 2021

Study completion Jul 31, 2021

Sponsor

Lead sponsor
Shaare Zedek Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Apr 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess Elelyso treatment on bone disease in Gaucher patients currently treated with other enzyme replacement therapy. Experience from early access program (2009-2012) has suggested that some patients who have been stable on imiglucerase have shown poor scores of QCSI with Fat Fraction below the cut off point of 0.23 which is considered "bone at risk", and have demonstrated remarkable improvement upon switching to Elelyso, including particularly 2 patients who did not have any change in dose or any drug interruption prior to the switch. These findings may be explained by the better glycan structure of imiglucerase (see Tekoah et al, 2013). The fact that in many patients prevention of bony complications is the main indication for ERT highlights the importance of this study, as all clinical trials of all ERTS heretofore did not include the bones as primary or secondary end-points but only as exploratory, and as such had only limited value,

Conditions

  • Gaucher Disease, Type 1

Interventions

  • quantitative chemical shift imaging (QCSI)Procedure

    Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered "bone at risk"

  • ElelysoDrug

    intravenous (IV) infusions of Elelyso

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QCSI results at 12 months, Fat fraction under 0.3.Time frame: 12 months
  2. QCSI results at 24 months, Fat fraction under 0.3.Time frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.